Goserelin extended release - Foresee Pharmaceuticals
Alternative Names: FP-011Latest Information Update: 06 Nov 2023
Price :
$50 *
At a glance
- Originator Foresee Pharmaceuticals
- Class Antineoplastics; Infertility therapies; Oligopeptides; Peptide hormones; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 06 Nov 2023 Goserelin extended release - Foresee Pharmaceuticals is available for licensing as of 06 Nov 2023. https://www.foreseepharma.com/en-us/prores/all
- 10 Oct 2023 Preclinical trial in Breast cancer in USA (unspecified route)